Augusto Galán Sarmiento: “Pharmaceutical policy must evolve from price to value”

A former Colombian health minister says insurers’ debts must be measured before they are paid, and that the system should pay for results.

Augusto Galán Sarmiento

VOICES · HEALTH INSURANCE · COLOMBIA

Augusto Galán Sarmiento
Photo: personal archive of Augusto Galán Sarmiento

Augusto Galán Sarmiento, a cardiologist, has been director general of Así Vamos en Salud, a Bogotá think-tank that tracks the performance of Colombia’s health system, since 2015. He was minister of health in 1995–96, under President Ernesto Samper, and Colombia’s ambassador to UNESCO, the United Nations’ educational, scientific and cultural agency, from 1999 to 2002. He has also led Colombia’s association of public hospitals and that of contributory-regime insurers, the Asociación Colombiana de Empresas de Medicina Integral (ACEMI), and holds a master’s in public administration from Harvard’s Kennedy School.

He speaks as Colombia’s new government, which took office on August 7th, prepares to decide the fate of the health insurers under state intervention. The health minister, Ana María Vesga, has said the future of each will be settled before the end of the year, although on October 22nd she said liquidation “should be the last of our alternatives or solutions.” A court provisionally suspended Coosalud’s intervention in October, and another did the same for Savia Salud’s in April. The 2027 budget, issued by decree on October 22nd after a procedural flaw in Congress, keeps the 2 trillion pesos added for health in the first debate but not 3 trillion more approved in the plenary votes that ended on October 20th. And in September the Constitutional Court ordered the health ministry to set the 2027 capitation payment unit (UPC), the per-member premium that funds insurers, on the basis of actual needs and to report back by January 15th; it also said the accumulated shortfall must be quantified.

In this written interview, he proposes three governance bodies, among them a technical regulatory commission whose members’ terms would outlast governments and a mechanism for deciding which technologies the system pays for, with a collective appeal against its decisions, as well as a national program to cut low-value care.

The interview

In “Recuperar el camino” (Getting back on track), your editorial for Así Vamos en Salud on August 6th, you proposed a sequence: stabilize the system, restore its governance, then move it forward. Which rules or bodies should be working by the end of the new government’s first year so that trust among the system’s players does not depend solely on who holds office?

At least three bodies are needed to strengthen institutions and the participation of citizens and civil society in the governance of our health system.

The first is a Health Regulatory Commission that would calculate the capitation payment unit (UPC), the annual premium paid for each citizen to finance their health care. It would also review what is included in and excluded from the benefits plan, and propose clinical practice guidelines. Its makeup must be strictly technical, with well-defined profiles covering the actuarial, epidemiological and financial aspects of that calculation. Its members must be chosen for their professional and technical qualifications. Their terms must outlast governments and not depend on them. It needs a great deal of autonomy, independent financing and access to information.

The second is a National Health Council with the participation of the system’s relevant players: users, patients, insurers, providers, doctors, local governments, academia and think-tanks, as an advisory council on public-health and social-security policy.

The third is the technical and scientific mechanism for incorporating health technologies: an overarching process that determines which health technologies will be assessed, why, on what criteria and by whom, how the discussion is organized and who takes part in it, along with a collective appeal process against its decisions.

At the end of 2025, according to the Comptroller General’s Office, 56.7% of members (29.7 million people) were in health insurers (entidades promotoras de salud, or EPS) under state intervention or other special measures; insurers under intervention or special measures held 82.7% of a total debt of 58.06 trillion pesos. Beyond finances, what should weigh in deciding which to restore and which to liquidate, so that patients’ treatment is not interrupted?

Deciding the future of the insurers under state intervention is perhaps the most complex decision to be taken in the medium term, amid the great complexity the health system faces. Liquidating one or several would create a very large systemic risk that could seriously affect the operation of the whole system. When a patient is unstable in intensive care, you don’t take them into major surgery without stabilizing them first. The financial-stabilization phase has to come first, and I see the government heading in that direction, which is good.

But of course, it is essential to understand better how those insurers are managing operational risk and primary risk. We can recapitalize them and inject all the liquidity we want, but if operational and primary risks are not well managed, no amount of money will be enough. The interventions have proven not to be the solution. The action of a single individual, the government-appointed administrator, with full powers and no governance checks and balances, is not the right path, and that has been demonstrated. I hope a way is found to return those insurers to their original owners. That requires planning the process very carefully and ensuring financial, legal and operational stability. A lot of patience, a lot of transparency and a lot of technical rigor.

“When a patient is unstable in intensive care, you don’t take them into major surgery without stabilizing them first.”

The superintendency found that Nueva EPS has no certified financial statements for 2023–25, and its government-appointed administrator estimated in September, on unaudited figures, that it owes providers 14.4 trillion pesos. The minister has warned that “it is not the state’s job to pay for the inefficiencies of its players.” Until there is a reconciled figure, how should the state decide which debts to recognize without letting hospitals, clinics and suppliers go under?

In my view, what is needed is clarity about the real size of the debt. How much is owed? To whom? Why? Who owes it? How and where did that debt arise? That is vital to solving the structural problem behind the crisis, and also to preventing something like this from happening again so that we can move toward a sustainable system, which is another fundamental discussion. Once that is achieved, we can separate the debt from current spending and then look at how it is going to be paid.

In the meantime, the first thing needed is to comply with the orders issued by the Constitutional Court, so as to quantify the shortfall in the calculation of the UPC over several years, as well as in the so-called maximum budget [presupuestos máximos] (which funds treatment of orphan diseases, among other things); that would inject liquidity into the system. Second, the UPC for 2027 must be calculated accurately and on a very technical basis.

THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Step 1 of 2 · Free. Work email for instant access. Unsubscribe anytime. By subscribing you agree to receive The HealthSignals Brief by email and accept our Privacy Policy.

You have said that demanding more money from the government is not enough. The Ministry of Health asked for an extra 13.9 trillion pesos for 2027 and the budget adds 2 trillion; the minister has also noted that more than 60% of Nueva EPS’s contracting is fee-for-service. Where could the system capture its biggest efficiency gains in 2027 without restricting patients’ access?

We need to establish a National Program for Reducing Low-Value Care and De-implementation, led by the Ministry of Health and Social Protection with ongoing technical support from the Institute for Health Technology Assessment (IETS), scientific societies, academia, insurers, providers, patients and local governments. We must identify and measure how much low-value practice is financed with health-system resources, and check that diagnostic tests are appropriate. Tests that are repeated on patients from one institution to the next are another source of inefficiency.

Users and patients can also help by canceling their appointments in advance when they cannot attend and, more generally, by learning to use the system effectively: a 28% no-show rate for consultations is excessive.* Provider networks must be organized around clear goals based on results and value, not simply on counting services and billing for them. We have to be more efficient in operations and in managing primary risk, and to get ahead of disease. And of course we need more transparency and more accountability from all players.

An Ombudsman’s Office survey of 2,042 users between January and August found that 87% had trouble getting their medicines and 46% ended up paying out of pocket. Insurers’ debts to pharmaceutical dispensing companies (operadores farmacéuticos) rose from 2.85 trillion to 3.8 trillion pesos in 2025, says the Comptroller General’s Office. How should those companies be contracted and paid so that medicines reach patients even when an insurer runs short of cash?

It is one thing for an insurer to have liquidity problems that affect its users’ and patients’ access to treatment, and another for every insurer’s liquidity to be hit and the whole value chain damaged: providers, logistics operators, health professionals, industry and, of course, patients. The first is a problem of administration and management at an individual insurer. The second is a systemic challenge.

An adequate, technical calculation of the UPC, with an updated methodology, is vital, and there has not been one in the past four years. That partly explains the increase in debt you mention. Now, at the more operational level, direct payment [in which the state pays providers and suppliers directly, on insurers’ behalf] is in my view a temporary and inefficient solution that is no substitute for proper management of operational and primary risks. One way forward, then, is to set up tripartite care and contracting arrangements (insurers, operators and industry), with prospective global payments based on value and with precise objectives. Pharmaceutical policy must evolve from price to value: paying for better results, not simply for the unit price of the service.

“We can recapitalize them and inject all the liquidity we want, but if operational and primary risks are not well managed, no amount of money will be enough.”

In 2024 you told El País that Colombia’s benefits plan “is wonderful,” but that the country has not tackled how to incorporate new technologies or how to build a process that would let it “set a limit and say no.” This year you have insisted that this must not make the right to health regressive. Which institution, and which criteria, would make prioritization legitimate to patients and judges?

One challenge we face as a society is guaranteeing that the fundamental right to health is sustainable for this generation and for future ones. Sustainability rests on two pillars: controlling and reducing inefficiency and waste, and distributive justice, so that innovation that generates value in health and well-being for the population can be incorporated in a dignified way.

The technical and scientific mechanism for sustainability that I mentioned requires several components. First, defining which technologies are to be assessed, determined by the Ministry of Health on the basis of epidemiological and demographic criteria. Second, strengthening the IETS and, more generally, the economic evaluation needed to show the health value of those technologies. Third, analysis and discussion so that the ethical and technical considerations of incorporating them are heard, in a space where the system’s players take part. Fourth, the decision, which is the Ministry of Health’s to take. Fifth, an appeal stage, which should be collective, whereas today it is individual, and should allow the decision to be reviewed in order to set criteria, including criteria for prioritizing access. This scheme should strengthen the legitimacy of decisions and the principle of progressive realization, through prioritization that takes people’s socioeconomic conditions into account.

*Galán Sarmiento told HealthSignals in writing that the 28% figure is drawn from data reported by insurers and health-care providers (instituciones prestadoras de servicios de salud, or IPS).

Disclosure: In a personal capacity, Galán Sarmiento is an independent member of the board of EPS Sura, an insurer. He has been director general of Así Vamos en Salud for 11 of its 24 years; he neither founded nor owns it. The think-tank says it works independently of the particular interests of its allies, which include social foundations, universities, insurers, providers and health-industry companies, among them EPS Sura itself, Fundación Keralty, Compensar, Sanofi, Roche, Johnson & Johnson, Boston Scientific, Medtronic and the actuarial firm Vela. Patients take part in its technical working groups.

Sources: Constitutional Court (Auto 1302 of 2026); Presidency of Colombia (Decree 1599 on the 2027 budget); El Colombiano (what the decree dropped); Vanguardia (3 trillion pesos added for health in the plenaries); La FM (minister Vesga on liquidation, October 22nd); Consultorsalud (Coosalud ruling); El Espectador (Savia Salud ruling); Consultorsalud (Comptroller General’s insurer report); El Universal/Colprensa (Comptroller General’s report); El Tiempo (Health Superintendency findings on Nueva EPS); Consultorsalud (Nueva EPS administrator’s debt estimate); El Espectador (minister Vesga on debts and fee-for-service); Semana (Ombudsman’s Office medicines survey); El País (interview, March 2024).

THE HEALTHSIGNALS BRIEF

A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.

Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.

Your subscription could not be validated.
You have successfully subscribed.

Comments

Related